Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.87 USD
+1.07 (22.29%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $5.78 -0.09 (-1.53%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FHTX 5.87 +1.07(22.29%)
Will FHTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Other News for FHTX
Flagship Pioneering Raises $3.6 Billion to Fuel Breakthrough Innovations that Transform Human Health and Sustainability
Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions
Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity under Strategic Partnership with Pfizer
Foghorn Therapeutics Unveils Strategic Plans to Investors
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June